In humans, peptide vaccination studies with HLA-A24/WT1235-243 epitopes have been well characterized in the literature to elicit WT1-specific CD8+ T-cell responses in adult and children cancer patients.9, 10, 11, 12, 13. This evidence concerns the gene CD8A and cancer.